Cellectis S.A. – NASDAQ:CLLS

Add to watchlist

$2.99

+1.58

+112.06%

Market closed

Open in about 6 hours

-32.54%

month

-32.54%

quarter

-59.37%

year

Market Cap	109.55M
Enterprise value	67.80M

P/E	-1.01
EV/Sales	3.07
EV/EBITDA	-0.87
Price/Sales	4.08
Price/Book	0.65
PEG ratio	1.97
EPS	-1.02

Revenue	5.14M
EBITDA	-84.11M
Income	-65.34M
Revenue Q/Q	3157.55%
Revenue Y/Y	-70.98%

Profit margin	-497.34%
Oper. margin	-636.4%
Gross margin	44.94%
EBIT margin	-636.4%
EBITDA margin	-1635.17%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Cellectis S.A. (NASDAQ:CLLS): Profit margin
Jun 2023	178K	-10.64M	-5982.02%
Sep 2023	155K	-17.48M	-11278.71%
Dec 2023	283K	-42.86M	-15145.58%
Mar 2024	4.52M	5.64M	124.62%

Cellectis S.A. Financials Estimate

Q Y

Cellectis S.A. (NASDAQ:CLLS): Analyst Estimates
Sep 2025	6.59M	-28.86M	-437.83%
Dec 2025	197.25K	-20.94M	-10620.42%
Dec 2025	10.61M	-28.86M	-272.02%
Mar 2026	3.07M	-33.79M	-1097.46%

Analysts Price target
Financials & Ratios estimates

Cellectis S.A. (NASDAQ:CLLS): Earnings per share (EPS)
2022-11-03	-0.46	-0.63
2023-03-08	-0.49029	-0.59

Cellectis S.A. (NASDAQ:CLLS): Debt to assets
Jun 2023	227674000	131.11M	57.59%
Sep 2023	209700000	133.57M	63.7%
Dec 2023	334270000	249.57M	74.66%
Mar 2024	354459000	263.89M	74.45%

Cellectis S.A. (NASDAQ:CLLS): Cash Flow
Jun 2023	-19.04M	-1.78M	19.81M
Sep 2023	-17.09M	-300K	1.68M
Dec 2023	39.61M	-13.65M	41.68M
Mar 2024	-23.54M	-2.05M	12.12M

Cellectis S.A. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Google Trends

Company's Focus On Multiple Cancers Including

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Company's Focus On Multiple Cancers Including
21 May 2023	12	1	7	34
28 May 2023	13	1	8	31
4 Jun 2023	13	1	15	32
11 Jun 2023	13	1	6	32
18 Jun 2023	14	1	6	32
25 Jun 2023	11	1	6	32
2 Jul 2023	11	1	6	35
9 Jul 2023	10	1	6	31
16 Jul 2023	10	1	5	31
23 Jul 2023	10	1	6	34
30 Jul 2023	12	1	7	34
6 Aug 2023	12	1	6	34
13 Aug 2023	10	1	6	32
20 Aug 2023	9	2	6	31
27 Aug 2023	10	1	6	32
3 Sep 2023	10	1	6	30
10 Sep 2023	10	1	6	30
17 Sep 2023	11	2	6	30
24 Sep 2023	10	1	6	35
1 Oct 2023	9	1	6	32

Gene editing

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Gene editing
21 May 2023	11
28 May 2023	12
4 Jun 2023	11
11 Jun 2023	12
18 Jun 2023	14
25 Jun 2023	15
2 Jul 2023	19
9 Jul 2023	18
16 Jul 2023	16
23 Jul 2023	27
30 Jul 2023	22
6 Aug 2023	16
13 Aug 2023	19
20 Aug 2023	16
27 Aug 2023	19
3 Sep 2023	20
10 Sep 2023	21
17 Sep 2023	23
24 Sep 2023	25
1 Oct 2023	21

Gene Editing Companies

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Gene Editing Companies
21 May 2023	24	1	4	10	16
28 May 2023	12	0	3	12	11
4 Jun 2023	18	0	5	15	4
11 Jun 2023	21	0	2	12	7
18 Jun 2023	18	0	5	9	7
25 Jun 2023	19	0	5	11	7
2 Jul 2023	16	1	6	21	7
9 Jul 2023	14	2	2	10	4
16 Jul 2023	14	0	3	11	9
23 Jul 2023	37	0	8	15	11
30 Jul 2023	25	1	7	15	11
6 Aug 2023	27	0	6	16	7
13 Aug 2023	21	7	4	10	4
20 Aug 2023	19	1	4	13	7
27 Aug 2023	17	0	8	13	8
3 Sep 2023	19	2	7	19	5
10 Sep 2023	22	1	5	20	6
17 Sep 2023	37	0	9	29	11
24 Sep 2023	47	0	11	31	29
1 Oct 2023	42	1	11	30	20

Types of gene editing

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Types of gene editing
5 Mar 2023	11	20	0
12 Mar 2023	12	18	0
19 Mar 2023	9	19	1
26 Mar 2023	9	21	0
2 Apr 2023	9	22	1
9 Apr 2023	21	31	0
16 Apr 2023	16	24	1
23 Apr 2023	13	23	1
30 Apr 2023	11	21	0
7 May 2023	10	61	0
14 May 2023	13	37	1
21 May 2023	9	30	1
28 May 2023	10	29	1
4 Jun 2023	10	24	1
11 Jun 2023	10	29	0
18 Jun 2023	10	29	1
25 Jun 2023	11	28	1
2 Jul 2023	9	35	1
9 Jul 2023	19	39	1
16 Jul 2023	100	34	0

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Cellectis S.A. (NASDAQ:CLLS): Job openings
Aug 2023	4
Sep 2023	2
Oct 2023	2
Nov 2023	1
Dec 2023	4
Jan 2024	4
Feb 2024	4
Apr 2024	4
May 2024	15
Jun 2024	30
Jul 2024	27
Dec 2024	9

Cellectis S.A. (NASDAQ:CLLS): Employee count
Aug 2023	231
Sep 2023	231
Oct 2023	231
Nov 2023	231
Dec 2023	231
Jan 2024	231
Feb 2024	231
Mar 2024	231
Apr 2024	231
May 2024	231
Jun 2024	216
Jul 2024	216

Cellectis S.A.
Hedge Funds Holdings Q1 2023

16.13% -3.06%

of CLLS is owned by hedge funds

20 -17

hedge funds hold CLLS stock

7.34M -1.38M

shares is hold by hedge funds

CLLS hedge funds holdings changes

Status	Patent	Filling date	Issue date
Application	Application UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLS Filling date: 30 Mar 2018 Issue date: 3 Jun 2021	30 Mar 2018	3 Jun 2021
Application	Application NEW UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T CELLS SPECIFIC FOR CD22 Filling date: 30 Mar 2018 Issue date: 8 Apr 2021	30 Mar 2018	8 Apr 2021
Application	Application PLANTS FOR PRODUCTION OF THERAPEUTIC PROTEINS Filling date: 13 Nov 2020 Issue date: 4 Mar 2021	13 Nov 2020	4 Mar 2021

Cellectis S.A.
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 30 May 2024	Q1 2024 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 4 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 5 May 2023	Q1 2023 Earnings Call Transcript

CLLS earnings call transcripts

Cellectis S.A.
Executives

Insider	Age	Since	Compensation
Dr. Andre Choulika Ph.D. (1965) Co-Founder, Chief Executive Officer & Director	60		$1,150,000
Dr. David J. D. Sourdive Ph.D. (1967) Co-Founder, Executive Vice President of CMC and Manufacturing & Director	58		$476,630

Cellectis S.A.
Latest News

Thursday, 12 December 2024
15:08	Cellectis: Poised To Start Answering Questions In 2025	seekingalpha.com
Tuesday, 10 December 2024
16:30	Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)	globenewswire.com
Tuesday, 5 November 2024
16:30	Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting	globenewswire.com
13:59	Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript	seekingalpha.com
Monday, 4 November 2024
16:30	Cellectis Provides Business Updates and Financial Results for Third Quarter 2024	globenewswire.com
Wednesday, 30 October 2024
16:30	Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024	globenewswire.com
Tuesday, 22 October 2024
02:00	Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress	globenewswire.com
Tuesday, 3 September 2024
16:30	Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety	globenewswire.com
Monday, 26 August 2024
16:30	Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors	globenewswire.com
Wednesday, 7 August 2024
02:00	Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer	globenewswire.com
Tuesday, 6 August 2024
16:30	Cellectis Provides Financial Results for the Second Quarter 2024	globenewswire.com
Thursday, 1 August 2024
16:30	FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment	globenewswire.com
Thursday, 25 July 2024
16:30	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment	globenewswire.com
Wednesday, 10 July 2024
10:37	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)	zacks.com
Friday, 28 June 2024
16:30	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024	globenewswire.com
Thursday, 20 June 2024
16:30	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing	globenewswire.com
Tuesday, 18 June 2024
13:01	Cellectis (CLLS) Upgraded to Buy: Here's Why	zacks.com
10:35	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)	zacks.com
Wednesday, 12 June 2024
16:30	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications	globenewswire.com
Tuesday, 4 June 2024
16:30	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia	globenewswire.com
Thursday, 30 May 2024
14:06	Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript	seekingalpha.com
09:14	Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024	seekingalpha.com
Wednesday, 29 May 2024
16:30	Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024	globenewswire.com
Tuesday, 28 May 2024
16:30	Cellectis Reports Financial Results for First Quarter 2024	globenewswire.com
Monday, 27 May 2024
16:30	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024	globenewswire.com
Monday, 6 May 2024
02:00	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	globenewswire.com
Thursday, 2 May 2024
16:30	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer	globenewswire.com
Monday, 29 April 2024
16:46	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023	globenewswire.com
Monday, 22 April 2024
16:30	Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	globenewswire.com
Wednesday, 10 April 2024
16:30	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs	globenewswire.com

Ideas & Opinions

Seeking Alpha 15 May 2025

Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Seeking Alpha 12 Dec 2024

Cellectis: Poised To Start Answering Questions In 2025
Seeking Alpha 30 May 2024

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
Seeking Alpha 3 Nov 2023

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
Seeking Alpha 29 Nov 2022

Iovance: Rolling BLA Development Signals More Upside
Seeking Alpha 2 Apr 2022

Allogene: Speculative CAR T Biotech With Big Potential In Oncology
Seeking Alpha 6 Sep 2021

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
Seeking Alpha 13 Jul 2021

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
Seeking Alpha 30 Jun 2021

CRISPR: 4 Emerging Players
Seeking Alpha 23 Jun 2021

Calyxt: Proprietary TALEN Plant-Technology Offers Multi-Industry Growth

Frequently Asked Questions (FAQ)

What's the price of Cellectis S.A. stock today?

One share of Cellectis S.A. stock can currently be purchased for approximately $2.99.
When is Cellectis S.A.'s next earnings date?

Unfortunately, Cellectis S.A.'s (CLLS) next earnings date is currently unknown.
Does Cellectis S.A. pay dividends?

No, Cellectis S.A. does not pay dividends.
How much money does Cellectis S.A. make?

Cellectis S.A. has a market capitalization of 109.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 96.06% to 755K US dollars. Cellectis S.A. made a loss 101.06M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.
What is Cellectis S.A.'s stock symbol?

Cellectis S.A. is traded on the NASDAQ under the ticker symbol "CLLS".
What is Cellectis S.A.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Cellectis S.A.?

Shares of Cellectis S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Cellectis S.A.'s key executives?
Cellectis S.A.'s management team includes the following people:
- Dr. Andre Choulika Ph.D. Co-Founder, Chief Executive Officer & Director(age: 60, pay: $1,150,000)
- Dr. David J. D. Sourdive Ph.D. Co-Founder, Executive Vice President of CMC and Manufacturing & Director(age: 58, pay: $476,630)
Is Cellectis S.A. founder-led company?

Yes, Cellectis S.A. is a company led by its founders Dr. Andre Choulika Ph.D. and Dr. David J. D. Sourdive Ph.D..
How many employees does Cellectis S.A. have?

As Jul 2024, Cellectis S.A. employs 216 workers, which is 6% less then previous quarter.
When Cellectis S.A. went public?

Cellectis S.A. is publicly traded company for more then 10 years since IPO on 24 Mar 2015.
What is Cellectis S.A.'s official website?

The official website for Cellectis S.A. is cellectis.com.
How can i contact Cellectis S.A.?

Cellectis S.A. can be reached via phone at +33 1 81 69 16 00.

Cellectis S.A.

cellectis.com

Exchange:

NASDAQ

Full time employees:

216

Industry:

Biotechnology

Sector:

Healthcare

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

+33 1 81 69 16 00

8, rue de la Croix Jarry
Paris, 75013

CIK: 0001627281
ISIN: US15117K1034
CUSIP: 15117K103